Who is sponsoring NCT05272696?

NCT05272696 is sponsored by Guangdong Provincial People's Hospital.

What drugs are being tested in NCT05272696?

Interventions in NCT05272696: Nab-paclitaxel, cisplatin and Pembrolizumab combination, surgery, Adjuvant Chemoradiotherapy, Radical concurrent chemoradiotherapy.

What condition does NCT05272696 study?

NCT05272696 studies Head and Neck Squamous Cell Carcinoma.

Is NCT05272696 still recruiting?

NCT05272696 is currently recruiting now. Last updated 1 July 2025.

Last reviewed 2025-07-01 · How we verify

NCT05272696

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

Recruiting now Phase 2 Last updated 1 July 2025

What this trial tests

Phase 2 trial testing Nab-paclitaxel, cisplatin and Pembrolizumab combination in Head and Neck Squamous Cell Carcinoma in 86 participants. Currently enrolling.

Timeline

1 March 2022

Primary endpoint
1 January 2026

1 January 2026

Quick facts

Lead sponsor	Guangdong Provincial People's Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	86
Start date	1 March 2022
Primary completion	1 January 2026
Estimated completion	1 January 2026
Sites	1 location across China

Drugs / interventions tested

Nab-paclitaxel, cisplatin and Pembrolizumab combination — full drug profile →
surgery
Adjuvant Chemoradiotherapy — full drug profile →
Radical concurrent chemoradiotherapy — full drug profile →

Conditions studied

Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →

Sponsor

Guangdong Provincial People's Hospital

Who can join

Adults 18 to 70, any sex, with Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study induction therapy with Nab-paclitaxel, Cisplatin and Pembrolizumab in patients with Locally Advanced HNSCC.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.
García-Domínguez DJ, López-Enríquez S, Alba G, Garnacho C, et al · · 2024 · cited 14× · PMID 38256268 · DOI 10.3390/ijms25021195
Immunomodulatory nanoplatforms with multiple mechanisms of action in cancer treatment.
Villa R, Shiau YP, Mahri S, Racacho KJ, et al · · 2025 · cited 1× · PMID 40331271 · DOI 10.1080/17435889.2025.2500906
Evaluation of neoadjuvant immunotherapy regimens for head and neck squamous cell carcinoma: a systematic review and single-arm and network meta-analysis.
Ye Z, Fan W, Zeng B, Tan R, et al · · 2026 · PMID 41504501 · DOI 10.1097/js9.0000000000004689

Verify or expand the search:

Other recruiting trials for Head and Neck Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
NCT07254585 — SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting

Other Guangdong Provincial People's Hospital trials

Trials by the same sponsor.

NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05272696 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
Last refreshed: 1 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05272696.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing